Pharmacological interaction of drugs with immune receptors: The p-i concept

Allergology International

Volumn 55, Issue 1, 2006, Pages 17-25

  Pichler, Werner J ^a   Beeler, Andreas ^a   Keller, Monika ^a   Lerch, Marianne ^a   Posadas, Sinforiano ^a   Schmid, Daphné ^a   Spanou, Zoi ^a   Zawodniak, Anna ^a   Gerber, Basil ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Drug hypersensitivity; Hapten; p i concept; Prohapten; T cells; T cell receptor

Indexed keywords

4 PHENYLENDIAMINE; CARBAMAZEPINE; CELECOXIB; CIPROFLOXACIN; DIAMINE DERIVATIVE; HAPTEN; LAMOTRIGINE; LIDOCAINE; MEPIVACAINE; SULFAMETHOXAZOLE; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CELL STIMULATION; CLINICAL FEATURE; COVALENT BOND; DENDRITIC CELL; DRUG EXPOSURE; HAPTEN CARRIER COMPLEX; HUMAN; HYBRIDOMA CELL CULTURE; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNE SYSTEM; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 33645766933     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.55.17     Document Type: Review

References (67)

1. Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective. Chem. Res. Toxicol. 1998;11:969-987.
2. Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf. 2000;23:483-507.
3. Pichler WJ. Delayed drug hypersensitivity reactions. Ann. Intern. Med. 2003;139:683-693.
4. Manfredi M, Severino M, Testi S et al. Detection of specific IgE to quinolones. J. Allergy Clin. Immunol. 2004;113:155-160.
5. Pichler WJ, Schnyder B, Zanni MP, Hari Y, von Greyerz S. Role of T cells in drug allergies. Allergy 1998;53:225-232.
6. Yawalkar N, Egli F, Hari Y, Nievergelt H, Braathen LR, Pichler WJ. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin. Exp. Allergy 2000;30:847-855.
7. Naisbitt DJ, Farrell J, Wong G et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J. Allergy Clin. Immunol. 2003;111:1393-1403.
8. Naisbitt DJ, Britschgi M, Wong G et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol. Pharmacol. 2003;63:732-741.
9. Pichler WJ. Immune mechanism of drug hypersensitivity. Immunol. Allergy Clin. North Am. 2004;24:373-397, v-vi.
10. Padovan E, Bauer T, Tongio MM, Kalbacher H, Weltzien HU. Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy. Eur. J. Immunol. 1997;27:1303-1307.
11. Cavani A, Hackett CJ, Wilson KJ, Rothbard JB, Katz SI. Characterization of epitopes recognized by hapten-specific CD4+ T cells. J. Immunol. 1995;154:1232-1238.
12. Cavani A, Mei D, Guerra E et al. Patients with allergic contact dermatitis to nickel and nonallergic individuals display different nickel-specific T cell responses. Evidence for the presence of effector CD8+ and regulatory CD4+ T cells. J. Invest. Dermatol. 1998;111:621-628.
13. Aiba S, Manome H, Nakagawa S et al. p 38 Mitogen-activated protein kinase and extracellular signal-regulated kinases play distinct roles in the activation of dendritic cells by two representative haptens, NiCl2 and 2,4-dinitrochlorobenzene. J. Invest. Dermatol. 2003;120:390-399.
14. Arrighi JF, Rebsamen M, Roussel F, Kindler V, Hauser C. A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J. Immunol. 2001;166:3837-3845.
15. Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 2002;3:196-200.
16. Gamerdinger K, Moulon C, Karp DR et al. A new type of metal recognition by human T cells: contact residues for peptide-independent bridging of T cell receptor and major histocompatibility complex by nickel. J. Exp. Med. 2003;197:1345-1353.
17. Lu L, Vollmer J, Moulon C, Weltzien HU, Marrack P, Kappler J. Components of the ligand for a Ni++ reactive human T cell clone. J. Exp. Med. 2003;197:567-574.
18. Griem P, Wulferink M, Sachs B, Gonzalez JB, Gleichmann E. Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol. Today 1998;19:133-141
19. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000;356:1587-1591.
20. Crispe IN. Hepatic T cells and liver tolerance. Nat. Rev. Immunol. 2003;3:51-62.
21. Bowen DG, Zen M, Holz L, Davis T, McCaughan GW, Bertolino P. The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J. Clin. Invest. 2004;114:701-712.
22. Kanny G, Pichler W, Morisset M et al. T cell-mediated reactions to iodinated contrast media: evaluation by skin and lymphocyte activation tests. J. Allergy Clin. Immunol. 2005;115:179-185.
23. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 2005;209:209-216.
24. Zanni MP, Mauri-Hellweg D, Brander C et al. Characterization of lidocaine-speciflc T cells. J. Immunol. 1997;158:1139-1148.
25. Schnyder B, Mauri-Hellweg D, Zanni M, Bettens F, Pichler WJ. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J. Clin. Invest. 1997;100:136-141.
26. Zanni MP, von Greyerz S, Schnyder B et al. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. J. Clin. Invest. 1998;102:1591-1598.
27. Zanni MP, von Greyerz S, Hari Y, Schnyder B, Pichler WJ. Recognition of local anesthetics by alphabeta+ T cells. J. Invest. Dermatol. 1999;112:197-204.
28. Sieben S, Kawakubo Y, Al Masaoudi T, Merk HF, Blomeke B. Delayed-type hypersensitivity reaction to paraphenylenediamine is mediated by 2 different pathways of antigen recognition by specific alphabeta human T-cell clones. J. Allergy Clin. Immunol. 2002;109:1005-1011.
29. Christiansen C, Pichler WJ, Skotland T. Delayed allergy-like reactions to X-ray contrast media: mechanistic considerations. Eur. Radiol. 2000;10:1965-1975.
30. Christiansen C. Late-onset allergy-like reactions to X-ray contrast media. Curr. Opin. Allergy Clin. Immunol. 2002;2:333-339.
31. Schmid DA DJ, Pichler WJ. T cell-mediated hypersensitivity to quinolones-mechanisms and crossreactivity. Clin. Exp. Allergy In press 2005.
32. Cribb AE, Spielberg SP. Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin. Pharmacol. Ther. 1992;51:522-526.
33. Naisbitt DJ, Vilar FJ, Stalford AC, Wilkins EG, Pirmohamed M, Park BK. Plasma cysteine deficiency and decreased reduction of nitrososulfamethoxazole with HIV infection [In Process Citation]. AIDS Res. Hum. Retroviruses 2000;16:1929-1938.
34. Schnyder B, Burkhart C, Schnyder-Frutig K et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. J. Immunol. 2000;164:6647-6654.
35. Burkhart C, von Greyerz S, Depta JP et al. Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells [In Process Citation]. Br. J. Pharmacol. 2001;132:623-630.
36. Zanni MP, von Greyerz S, Schnyder B, Wendland T, Pichler WJ. Allele-unrestricted presentation of lidocaine by HLA-DR molecules to specific αβ + T cell clones. Int. Immunol. 1998;10:507-515.
37. von Greyerz S, Bultemann G, Schnyder K et al. Degeneracy and additional alloreactivity of drug-specific human alpha beta (+) T cell clones. Int. Immunol. 2001;13:877-885.
38. Burkhart C, Britschgi M, Strasser I et al. Non-covalent presentation of sulfamethoxazole to human CD4+ T cells is independent of distinct human leucocyte antigen-bound peptides. Clin. Exp. Allergy 2002;32:1635-1643.
39. Depta JP, Altznauer F, Gamerdinger K, Burkhart C, Weltzien HU, Pichler WJ. Drug interaction with T-cell receptors: T-cell receptor density determines degree of cross-reactivity. J. Allergy Clin. Immunol. 2004;113:519-527.
40. Vollmer J, Weltzien HU, Dormoy A, Pistoor F, Moulon C. Functional expression and analysis of a human HLA-DQ restricted, nickel-reactive T cell receptor in mouse hybridoma cells. Journal of Investigative Dermatology 1999;113:175-181.
41. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr. Opin. Allergy Clin. Immunol. 2002;2:301-305.
42. Thierse HJ, Gamerdinger K, Junkes C, Guerreiro N, Weltzien HU. T cell receptor (TCR) interaction with haptens: metal ions as non-classical haptens. Toxicology 2005;209:101-107.
43. Beeley NR. Can peptides be mimicked? Drug Discov. Today 2000;5:354-363.
44. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol. Today 1998;19:395-404.
45. Pichler WJ. Lessons from drug allergy: against dogmata. Curr. Allergy Asthma Rep. 2003;3:1-3.
46. Pichler WJ. Direct T-cell stimulations by drugs-bypassing the innate immune system. Toxicology 2005;209:95-100.
47. Gerber BO, Pichler WJ. Cellular mechanisms of T cell mediated drug hypersensitivity. Curr. Opin. Immunol. 2004;16:732-737.
48. Pirmohamed M, Park BK. HIV and drug allergy. Curr. Opin. Allergy Clin. Immunol. 2001;1:311-316.
49. Pichler WJ. Predictive drug allergy testing: an alternative viewpoint. Toxicology 2001;158:31-41.
50. Hashimoto K, Yasukawa M, Tohyama M. Human herpes-virus 6 and drug allergy. Curr. Opin. Allergy Clin. Immunol. 2003;3:255-260.
51. Sekiguchi A, Kashiwagi T, Ishida-Yamamoto A et al. Drug-induced hypersensitivity syndrome due to mexiletine associated with human herpes virus 6 and cytomegalovirus reactivation. J. Dermatol. 2005;2:278-281.
52. Hari Y, Frutig-Schnyder K, Hurni M et al. T cell involvement in cutaneous drug eruptions. Clin. Exp. Allergy 2001;31:1398-1408.
53. Engler OB, Strasser I, Naisbitt DJ, Cerny A, Pichler WJ. A chemically inert drug can stimulate T cells in vivo by their T cell receptor in non-sensitised individuals. Toxicology 2004;197:47-56.
54. Bala S, Weaver J, Hastings KL. Clinical relevance of preclinical testing for allergic side effects. Toxicology 2005;209:195-200.
55. Naisbitt DJ, Gordon SF, Pirmohamed M et al. Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br. J. Pharmacol. 2001;133:295-305.
56. Naisbitt DJ, Farrell J, Gordon SF et al. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation. Mol. Pharmacol. 2002;62:628-637.
57. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 2001;22:298-305.
58. Pirmohamed M, Park BK. Cytochrome P 450 enzyme polymorphisms and adverse drug reactions. Toxicology 2003;192:23-32.
59. Alfirevic A, Stalford AC, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M. Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. Br. J. Clin. Pharmacol. 2003;55:158-165.
60. Pirmohamed M, Lin K, Chadwick D, Park BK. TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology 2001;56:890-896.
61. Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-732.
62. Martin AM, Nolan D, Gaudieri S et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. U. S. A. 2004;101:4180-4185.
63. Chung WH, Hung SI, Hong HS et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486.
64. Hung SI, Chung WH, Liou LB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. U. S. A. 2005;102:4134-4139.
65. Stockl J, Majdic O, Fischer G, Maurer D, Knapp W. Monomorphic molecules function as additional recognition structures on haptenated target cells for HLA-A1-restricted, hapten-speciflc CTL. J. Immunol. 2001;167:2724-2733.
66. Nassif A, Bensussan A, Dorothee G et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J. Invest. Dermatol. 2002;118:728-733.
67. Britschgi M, Steiner UC, Schmid S et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J. Clin. Invest. 2001;107:1433-1441.